LLY vs MCK
LLY: Eli Lilly is a global pharmaceutical innovator leading the market in metabolic health, including diabetes and obesity treatments, alongside a diverse portfolio of oncology and immunology therapies. MCK: A global leader in pharmaceutical distribution and healthcare technology services, connecting biopharma, providers, and patients to improve care outcomes.
Side-by-side fundamentals
| Metric | LLY | MCK | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $1,169.60 | $930.25 | |
| Market cap | $1.10T | $108.5B | |
| P/E as of 2026-10-08 | 39.25 | 24.91 | MCK lower |
| PEG | 0.80 | 1.63 | LLY lower |
| Net margin | +31.7% | +1.2% | LLY higher |
| Gross margin FY2026, SEC XBRL | n/a | +3.6% | |
| Operating margin FY2026, SEC XBRL | n/a | +1.5% | |
| ROE FY2025, SEC XBRL | +77.8% | n/a | |
| ROA | +18.4% | +5.8% | LLY higher |
| Debt / equity as of 2026-09-03 | 1.62 | 1.29 | MCK lower |
| Revenue growth (YoY) as of 2026-09-03 | +49.6% | +8.8% | LLY higher |
| Revenue CAGR (3y) SEC XBRL | +31.7% | +13.4% | LLY higher |
| Dividend yield as of 2026-09-03 | +0.6% | +0.4% | LLY higher |
| Dividend streak (yrs) SEC XBRL | 10 | 19 | MCK higher |
| Beta as of 2026-09-03 | 0.55 | 0.06 | |
| 1-year return as of 2026-10-08 close | +38.3% | +23.1% | LLY higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.